Why the study?
Sustained ventricular tachycardia is an uncommon initial manifestation of transthyretin amyloid cardiomyopathy, and management of ventricular arrhythmias and ICD use in these patients is limited and uncertain.
Does implantable cardioverter-defibrillator and ATTR-stabilizer therapy prevent recurrent ventricular arrhythmias in a patient with hereditary transthyretin amyloid cardiomyopathy?
Case Report (n=1)
Does implantable cardioverter-defibrillator and ATTR-stabilizer therapy prevent recurrent ventricular arrhythmias in a patient with hereditary transthyretin amyloid cardiomyopathy?
Sustained ventricular tachycardia can be a rare initial presentation of hereditary ATTR-CM, and individualized management with an ICD and disease-modifying therapy may lead to long-term stability.
May support long-term arrhythmia stability with ICD and ATTR-stabilizer in hereditary ATTR-CM with VT; leaves open broader efficacy.
BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) most commonly presents with heart failure symptoms. Sustained ventricular tachycardia (VT) is an uncommon initial manifestation. CASE SUMMARY: A 57-year-old man presented with hemodynamically unstable monomorphic VT requiring cardioversion. Imaging suggested cardiac amyloidosis and bone scintigraphy demonstrated Perugini grade 3 uptake. Genetic testing revealed a pathogenic p.Glu109Gln variant in the transthyretin gene. An implantable cardioverter-defibrillator (ICD) was implanted, and ATTR-stabilizer therapy was initiated. The patient remains stable without recurrent VT after 2.5 years. DISCUSSION: This case highlights VT as a rare initial presentation of ATTR-CM and emphasizes the limited evidence guiding the management of ventricular arrhythmias and the role of ICDs in these patients. Notably, the patient remained free of recurrent ventricular arrhythmias and ICD therapies during 2.5 years of follow-up without antiarrhythmic therapy. TAKE-HOME MESSAGES: VT may represent an atypical presentation of ATTR-CM. Management of ventricular arrhythmias remains individualized due to limited evidence.
No takes yet. Share an insight, caveat, or question.
Weiss et al. (2026) conducted a case report in Transthyretin amyloid cardiomyopathy (ATTR-CM) with sustained ventricular tachycardia (n=1). Implantable cardioverter-defibrillator (ICD) and ATTR-stabilizer therapy was evaluated on Recurrence of sustained ventricular arrhythmias or ICD therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: